Geron Corporation Stock Price and Value Analysis

Should you buy Geron Corporation stock? (NasdaqGS:GERN). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This company is not making money.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the GERN Numbers

GERN Price
(Geron Corporation stock price per share)
[?] PE Ratio versus Sector 1220% higher than other Healthcare stocks
[?] PE Ratio versus Industry 362% higher than other Biotechnology stocks
[?] Cash Yield -3.27%
[?] Free Cash Flow Jitter 50%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 14,359,737 shares shorted. With 346,792,389 shares available for purchase and an average trading volume over the past 10 trading days of 4,105,450, it would take at least 3.498 days for all of the short holders to cover their shorts.

Is Geron Corporation Stock on Sale?

Based on our analysis, we believe that you should not buy Geron Corporation right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy GERN Stock?

Does Geron Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.